Tags

Type your tag names separated by a space and hit enter

Tolterodine for the treatment of urge urinary incontinence.
Expert Opin Pharmacother. 2013 Oct; 14(14):1987-91.EO

Abstract

INTRODUCTION

Overactive bladder (OAB) and its resultant urge urinary incontinence (UUI) are significant problems that medically, psychologically and financially affect people. The constellation of symptoms comprising OAB affects ∼ 16% of the adult population and its prevalence increases with aging. The typical class of medications used to treat OAB is antimuscarinics.

AREAS COVERED

OAB medications, with a focus on tolterodine for the treatment of UUI are reviewed. A thorough review of English language literature using EMBASE/Medline and PubMed has been performed.

EXPERT OPINION

Tolterodine provides a reasonable starting point when treating patients with OAB and UUI. Efficacy and tolerability are generally comparable between tolterodine and other newer antimuscarinics. Tolterodine is a good option as part of the algorithm in the treatment of OAB and UUI.

Authors+Show Affiliations

Weill Cornell Medical College of Cornell University, James Buchanan Brady Department of Urology , 425 East 61st Street, 12th floor, New York, NY 10065 , USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

23885788

Citation

Elterman, Dean S., et al. "Tolterodine for the Treatment of Urge Urinary Incontinence." Expert Opinion On Pharmacotherapy, vol. 14, no. 14, 2013, pp. 1987-91.
Elterman DS, Chughtai B, Kaplan SA, et al. Tolterodine for the treatment of urge urinary incontinence. Expert Opin Pharmacother. 2013;14(14):1987-91.
Elterman, D. S., Chughtai, B., Kaplan, S. A., & Barkin, J. (2013). Tolterodine for the treatment of urge urinary incontinence. Expert Opinion On Pharmacotherapy, 14(14), 1987-91. https://doi.org/10.1517/14656566.2013.823158
Elterman DS, et al. Tolterodine for the Treatment of Urge Urinary Incontinence. Expert Opin Pharmacother. 2013;14(14):1987-91. PubMed PMID: 23885788.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tolterodine for the treatment of urge urinary incontinence. AU - Elterman,Dean S, AU - Chughtai,Bilal, AU - Kaplan,Steven A, AU - Barkin,Jack, Y1 - 2013/07/26/ PY - 2013/7/27/entrez PY - 2013/7/28/pubmed PY - 2014/3/26/medline SP - 1987 EP - 91 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 14 IS - 14 N2 - INTRODUCTION: Overactive bladder (OAB) and its resultant urge urinary incontinence (UUI) are significant problems that medically, psychologically and financially affect people. The constellation of symptoms comprising OAB affects ∼ 16% of the adult population and its prevalence increases with aging. The typical class of medications used to treat OAB is antimuscarinics. AREAS COVERED: OAB medications, with a focus on tolterodine for the treatment of UUI are reviewed. A thorough review of English language literature using EMBASE/Medline and PubMed has been performed. EXPERT OPINION: Tolterodine provides a reasonable starting point when treating patients with OAB and UUI. Efficacy and tolerability are generally comparable between tolterodine and other newer antimuscarinics. Tolterodine is a good option as part of the algorithm in the treatment of OAB and UUI. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/23885788/Tolterodine_for_the_treatment_of_urge_urinary_incontinence_ L2 - https://www.tandfonline.com/doi/full/10.1517/14656566.2013.823158 DB - PRIME DP - Unbound Medicine ER -